What this article helps you consider
- Separate content from release
- Consider physical changes in the dosage form
- Confirm that the measurement is reliable
Separate content from release
Assay determines how much active ingredient is present under the conditions of the analytical procedure. Dissolution measures release into a defined medium over time. The tests describe different attributes. A successful assay therefore cannot compensate for an unacceptable dissolution result where dissolution is a required quality attribute.
Dissolution is especially useful during formulation development because it can reveal changes that are not obvious from appearance or content. Its interpretation depends on the procedure’s suitability for the product and on the relationship between the observed result and the relevant specification. R10R11
Consider physical changes in the dosage form
Moisture can affect disintegrants, binders and the compact structure. Coatings may continue to cure or change permeability. The active ingredient can undergo a solid-state change, while interactions with excipients can affect wetting or release. Gelatin capsules may exhibit cross-linking in some circumstances. None of these explanations should be assumed without evidence.
A useful first step is to compare dissolution with water content, disintegration, mechanical properties and any relevant solid-state observations. A trend that follows moisture uptake suggests a different investigation from one that follows a coating-process change. The aim is to identify a mechanism that explains the full pattern of results.
Confirm that the measurement is reliable
Before changing the formulation, review medium preparation, pH, temperature, agitation, deaeration where applicable, apparatus condition, sampling timing and filtration. Verify that the analyte remains stable in the medium and does not adsorb to the sampling system. Product variability and analytical variability must be distinguished.
The method should be sufficiently sensitive to meaningful product differences. A highly solubilising medium may make several formulations look alike even when they behave differently under other conditions. Conversely, an unsuitable condition can create variability with little relevance to product quality. Selectivity for a failure mechanism and routine reproducibility must be considered together.
Compare profiles rather than one convenient point
Multiple time points can reveal delayed onset, a lower plateau or a change in release rate. The illustration uses invented data to show a product with similar eventual release but slower early dissolution after storage. These curves do not establish bioequivalence, clinical impact or a regulatory failure.
Invented teaching data; not Stabicon experimental results. No specification, bioequivalence or clinical outcome is implied.
Formal profile comparison must follow the relevant method and statistical conditions. The similarity factor f2 is not appropriate for every dataset, particularly where variability, sampling or release characteristics violate its assumptions. Review individual units as well as averages; an acceptable mean may conceal units with distinctly different performance. R10
Link packaging and process to the investigation
If the change appears only in one pack, compare barrier performance, closure application, desiccant capacity and fill configuration. If it occurs across packs, examine formulation and process variables such as granulation endpoint, lubrication and coating. Use targeted experiments to test the leading explanations rather than changing several factors simultaneously without a design.
For a hypothetical coated tablet, investigate whether a storage-related slowdown follows coating weight gain or curing conditions. Compare matched batches and document whether the proposed adjustment changes impurities, mechanical performance or other attributes. A faster profile is not automatically preferable, particularly for modified-release products.
Establish a control strategy
Once a mechanism is supported, define material, process and packaging controls that reduce its recurrence. Confirm the solution on representative batches and incorporate the appropriate stability tests. Do not resolve an adverse trend by selecting a less discriminating method without a justified scientific and regulatory basis.
Stabicon can combine dissolution testing, stability observations and formulation investigation to help identify why product performance changes and what evidence is needed to control it. This article focuses on pharmaceutical dosage forms; supplement testing should be selected for the applicable product category and market.
References & further reading
Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.
- R01ICH Q1A R2 Stability Testing of New Drug Substances and Products
Final guideline, 2003. Pharmaceutical scope; apply target-authority requirements.
- R10FDA Dissolution Testing of Immediate Release Solid Oral Dosage Forms
Final guidance, 1997. Pharmaceutical dissolution and profile comparison principles.
- R11ICH Q6A Specifications for Chemical Drug Substances and Products
FDA guidance page. Pharmaceutical specifications and dosage-form considerations.
From insight to a defined programme
Bring your next technical question.
Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.
Discuss this topic with Stabicon






